Anebulo Pharmaceuticals, Inc. (ANEB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0345691036
Anebulo Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -9.22 m USD |
| EBIT | -8.08 m USD |
| Net income | -8.48 m USD |
| Diluted EPS – continuing operations | -0.25 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
More stocks
- Adia Nutrition, Inc. (ADIA)
- Magnolia Bancorp, Inc. (MGNO)
- AVAI BIO, INC. (AVAI)
- Trutankless, Inc. (TKLS)
- INNSUITES HOSPITALITY TRUST (IHT)
- GLEN BURNIE BANCORP (GLBZ)
- VerifyMe, Inc. (VRME)
- LeonaBio, Inc. (LONA)
- UNIVERSAL SAFETY PRODUCTS, INC. (UUU)
- URBAN ONE, INC. (UONE)
- Clean Energy Technologies, Inc. (CETY)
- Thunder Power Holdings, Inc. (AIEV)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.